reports
Alphawave IP Group: 1 director
A director at Alphawave IP Group maiden bought 100,000 shares at 117p and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Form 8.3 - Mattioli Woods
Form 8.3 - Mattioli Woods 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: ...
Enovix to Participate in Upcoming Investor Conferences
Enovix to Participate in Upcoming Investor Conferences FREMONT, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced its participation in the following investor conferences in May and June: J.P. Morgan 52nd Annual Global Technology, Media, and Communications ConferenceDate: Tuesday, May 21, 2024Location: Boston, Mass.Presentation: 4:25 PM ETWebcast link: Available B. Riley 23rd Annual Institutional Investor ConferenceDate: Thursday, May 23, 2024Location: Beverly Hills, Calif. Craig-Hallum 20th Annual Inst...
Pantoro Limited: 1 director
A director at Pantoro Limited sold 1,000,000 shares at 0.086AUD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Gear Energy Ltd: 1 director
A director at Gear Energy Ltd bought 705,500 shares at 0.730CAD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Form 8.3 - Lok’n Store Group PLC
Form 8.3 - Lok’n Store Group PLC 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form re...
RadNet’s Lenox Hill Radiology to Host Mother’s Day Mammogram Screening...
RadNet’s Lenox Hill Radiology to Host Mother’s Day Mammogram Screening Parties in New York City WNBA icon Sheryl Swoopes and New York elected officials will attend “MammoGlam” events in Harlem and the Bronx to promote breast health and equitable access NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announced two events to promote breast health and equitable access to crucial cancer screening services. In collaboration with Lenox Hill Radiology, RadNet will h...
Landstar to Participate in Bank of America 2024 Annual Investment Conf...
Landstar to Participate in Bank of America 2024 Annual Investment Conference JACKSONVILLE, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Landstar System, Inc. (NASDAQ:LSTR) announced today its participation in the Bank of America 2024 Annual Investment Conference. Landstar’s “fireside chat” discussion begins at 10:20 a.m. ET on Tuesday, May 14. It will be broadcast live via the Internet at ; click on "Webcasts." The Bank of America 2024 Annual Investment Conference webcast will be available on Landstar’s website through May 22. For more information about the webcast, please contact Landstar’s In...
Form 8.3 - Balanced Commercial Property Trust Limited
Form 8.3 - Balanced Commercial Property Trust Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant se...
Raffles Medical Group Ltd: 1 director
A director at Raffles Medical Group Ltd bought 500,000 shares at 1.000SGD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Hunan Coran New Energy Co Ltd: 3 directors
Three Directors at Hunan Coran New Energy Co Ltd bought 63,600 shares at between 4.246CNY and 4.280CNY. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Form 8.3 - Alpha Financial Markets Consulting Plc
Form 8.3 - Alpha Financial Markets Consulting Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securi...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psy...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusiv...
Moody's Ratings affirms Equinor's Aa2 senior unsecured ratings; outloo...
Moody's Ratings (Moody's) has today affirmed the Aa2 senior unsecured and backed senior unsecured debt ratings of Norwegian oil major Equinor ASA ("Equinor"), as well as the company's (P)Aa2 backed senior unsecured MTN program rating, its P-1/(P)P-1 commercial paper and backed other short-term ratin...
Moody's Ratings affirms KfW IPEX-Bank's Aa2 long-term deposit ratings,...
Moody's Ratings (Moody's) today affirmed KfW IPEX-Bank GmbH (IPEX-Bank)'s Aa2/P-1 long- and short-term deposit and Counterparty Risk Ratings (CRR). The outlook on the bank's long-term deposit ratings remains stable. At the same time, Moody's affirmed IPEX-Bank's a3 Baseline Credit Assessment (BCA)...
Form 8.3 - Abrdn European Logistics Income Plc
Form 8.3 - Abrdn European Logistics Income Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securitie...
Tompkins Financial Corp: 1 director
A director at Tompkins Financial Corp sold 4,099 shares at 0.000USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or sec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.